Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Armodafinil is an FDA approved medication with wakefulness-promoting properties. It is a
relatively safe agent with interesting neurochemical effects on the catecholamine system,
producing an improvement in cognitive function, particularly working memory in humans. When
combined with intensive task-related training, armodafinil may accelerate motor recovery in
chronic stroke patients.
The primary aim of this study is to determine whether administration of armodafinil during
subacute post-stroke rehabilitation will augment cortical plasticity and enhance motor
recovery. The primary hypothesis suggests that cortical plasticity will be enhanced by
armodafinil and, therefore, will induce an improvement in motor function and better
performances on measures of motor control.
Phase:
Phase 2
Details
Lead Sponsor:
Burke Rehabilitation Hospital
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries